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Summary
Two reports have been published suggesting an
association between the personality trait of novelty
seeking and the DRD4*7R allele at the D4 dopamine-
receptor locus (with heterozygotes or homozygotes
for DRD4*7R having higher novelty seeking). We
studied novelty seeking and four coding-sequence
polymorphisms affecting protein structure in the D4
dopamine-receptor gene (DRD4) in a sample of 341
American subjects, of whom 224 are of primarily
European ancestry and 117 are of primarily African
ancestry. These subjects had diagnoses of substance
dependence or personality disorder (PD) or were
screened to exclude major psychiatric diagnosis. We
found that, although the substance-dependent subjects
had significantly higher novelty seeking than the control
and PD subjects, they did not differ in DRD4*7R allele
frequency. There was no association between any DRD4
polymorphism and novelty seeking in any population or
diagnostic group, except for a significant association
between the DRD4*7R allele and lower novelty seeking
among European American females and African
American substance abusers. The novelty seeking of
subjects heterozygous for a null mutation did not differ
from that of subjects with two functional alleles. We
conclude that the most likely explanation of these results
is that the DRD4 VNTR does not influence directly the
trait of novelty seeking, in these samples.
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Introduction
Dopamine is one of the most important neurotransmit-
ters in the brain, and dopamine-receptor genes have been
the subject of numerous candidate-gene studies in psy-
chiatry. The D4 dopamine-receptor gene, DRD4 (Van
Tol et al. 1991), has been one of the most studied, owing
to the protein product’s interesting ligand-binding prop-
erties (Van Tol et al. 1991), its location in limbic brain
areas (Van Tol et al. 1991; Meador-Woodruff et al.
1994), the presence of several coding-region polymor-
phisms (Van Tol et al. 1992; Catalano et al. 1993;
No¨then et al. 1994; Seeman et al. 1994), and the effects
of those polymorphisms on ligand binding (discussed
below). DRD4 maps to distal chromosome 11p (Gel-
ernter et al. 1992), proximal to HRAS (Petronis et al.
1993).
We have reported linkage disequilibrium between the
seven-repeat allele at a DRD4 VNTR polymorphism
(DRD4*7R) and Tourette syndrome, using the Spielman
transmission-disequilibrium test (Grice et al. 1996).
DRD4 alleles recently have been reported to be associ-
ated with personality measures, specifically novelty seek-
ing (Benjamin et al. 1996; Ebstein et al. 1996). Persons
with high novelty seeking are described as “impulsive,
exploratory, excitable, disorderly and distractible”
(Cloninger 1987, p. 411). According to one article (Ben-
jamin et al. 1996), allelic variation at DRD4 may ac-
count for 10% of the genetic variation of novelty seek-
ing. Ebstein et al. (1996) studied 124 unrelated Israeli
subjects; the DRD4*7R allele was found to be associated
with higher novelty seeking, independent of ethnicity,
sex, or age. Benjamin et al. (1996) studied 315 siblings,
most of whom were males, family members, and unre-
lated individuals from the United States and found an
association of so-called long alleles (DRD4*7R and
DRD4*8R) with novelty seeking; stratification was ex-
cluded as an explanation, on the basis of the sibling-pair
data. Although these two reports were consistent, the
findings could not be replicated in Finnish (Malhotra et
al. 1996) or Swedish (Jo¨nsson et al. 1997) subjects.
Several factors suggested, beforehand, that the find-
ings might be difficult to replicate. Patients with type 2
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alcoholism (a subtype that is thought to be particularly
heritable) and substance dependence are expected to
have relatively high novelty seeking (Cloninger 1987).
Since alcohol- and drug-dependent subjects have high
novelty seeking, the allele associated with novelty seek-
ing (DRD4*7R) should be observed at an increased fre-
quency in a sample of alcohol- and drug-dependent sub-
jects. Previously published results (George et al. 1993;
Adamson et al. 1995; Muramatsu et al. 1996) suggest,
however, that there is no association of the DRD4*7R
allele with alcohol dependence.
Also, a moderate degree of assortative mating exists
for certain features of personality (Feng and Baker
1994), so random mating does not apply for genetic loci
affecting these personality features, and, if the effects are
strong enough, there consequently should be a deviation
from Hardy-Weinberg equilibria (HWE) expectations at
such loci. If DRD4 alleles really affected personality to
a significant degree, there should be an increase in mat-
ings of persons with like genotypes and increased ob-
served homozygosity for the operant alleles, with an in-
crease in observed DRD4*7R homozygotes. However,
to our knowledge, no deviation from HWE expectations
has been reported at this locus. It was with these con-
siderations in mind that we studied DRD4 allele fre-
quencies in subjects dependent on alcohol, cocaine, or
heroin; in subjects with personality disorders (PDs); and
in normal control subjects.
In addition to the exon 3 VNTR, which is the most
studied variant at this locus, there exist at least three
additional coding-sequence variations that also affect the
amino acid sequence. Two are in exon 1 (a 12-bp du-
plication of unknown functional effect but reported to
be associated with psychosis [Catalano et al. 1993] and
a 13-bp deletion resulting in a null allele [No¨then et al.
1994]). An additional single-base mutation, D4194Glycine,
in exon 3 was observed previously only in individuals
of African ancestry; the protein product exhibits activity
that is two orders of magnitude lower than that of the
normal D4 receptor (Seeman et al. 1994; Liu et al. 1996);
therefore, it is nearly a null mutation also.
Published studies (including Benjamin et al. 1996; Eb-
stein et al. 1996; Malhotra et al. 1996) have considered
primarily the exon 3 VNTR polymorphism (Van Tol et
al. 1992; Asghari et al. 1994, 1995). This polymorphism
consists of a variable number of 48-bp tandem repeats
located in the third cytoplasmic loop of the correspond-
ing protein (Van Tol et al. 1991; Lichter et al. 1993).
The initial expression study of cDNA for cloned receptor
variants and two subsequent studies reported different
properties for the alleles with seven repeats (DRD4*7R),
compared with the two other most common alleles
(DRD4*2R and DRD4*4R), with respect to clozapine
and spiperone binding or to other functional measures
(Van Tol et al. 1992; Asghari et al. 1994, 1995). Rarer
VNTR alleles, for example, DRD4*8R, were not stud-
ied. It is possible that, for any of these studies, the ob-
served effects were conveyed by sequence differences
other than those at the identified exon 3 site (e.g., one
of the other three known coding-region variants dis-
cussed above). We studied all four known DRD4 coding-
region variants but did not distinguish between different
VNTR alleles of identical length but of differing
sequence.
Subjects and Methods
Subjects
Subjects were assessed at one of three sites, as de-
scribed below. Informed consent was obtained from all
subjects. Assessment at the different sites was as follows:
1. University of Connecticut Health Center (UCHC),
Farmington (162 substance-dependent subjects, 5 PD
subjects, and 48 controls). Control subjects were as-
sessed by use of the SCID (Structured Clinical Interview
from the Diagnostic and Statistical Manual of Mental
Disorders, 3d ed., rev. [DSM-III-R] [American Psychi-
atric Association 1987]) (Spitzer et al. 1992) and the
SCID II (First et al. 1995) and were evaluated to exclude
those with a major axis I psychiatric disorder. The PD
subjects were evaluated in the same manner as that used
for the controls but were found to have PDs. Substance-
dependent subjects were diagnosed, by use of SCID, with
either alcohol or drug dependence or both; schizophre-
nia was an exclusion criterion. Novelty seeking was
assessed by use of the Temperament and Character In-
ventory, in which the Tridimensional Personality Ques-
tionnaire (TPQ) (Cloninger et al. 1991) is embedded.
2. Medical College of Pennsylvania–Hahnemann
School of Medicine (MCP) (87 subjects [63 with PDs
and 24 controls]). Diagnostic procedures are summa-
rized elsewhere (Coccaro et al. 1996). In brief, diagnoses
were made by use of DSM-III-R and were assigned by
a best-estimate process based on information obtained
by interviews using the Schedule for Affective Disorders
and Schizophrenia (SADS) (Spitzer and Endicott 1975)
and the Structured Interview for the Diagnosis of Per-
sonality Disorder, revised (SIDP-R) (Pfohl et al. 1989),
by clinical interviews by a research psychiatrist, and by
review of all other available clinical data. Novelty seek-
ing was assessed by use of the TPQ (Cloninger et al.
1991).
3. Mt. Sinai School of Medicine (MSSOM), New York
(39 subjects, all with PDs). Subjects were evaluated by
use of the SADS (Spitzer and Endicott 1975). All subjects
with PDs were interviewed by one rater, with the
SIDP-R (Pfohl et al. 1989); a second rater administered
an independent SIDP to an individual close to the sub-
ject. Consensus diagnoses were reached in a meeting of
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all raters, with an expert diagnostician. Novelty seeking
was assessed by use of the TPQ (Cloninger et al. 1991).
A total of 341 subjects, of whom 204 (59.8%) were
male, participated in the study. A significantly greater
proportion of the PD patients were male (72.9%), com-
pared with that of the controls (52.8%) and that of the
substance-dependent patients (54.3%) ( , 22x  11.13
df, ). The subject group was 65.7% EuropeanP  .004
American and 34.3% African American. A significantly
greater proportion of controls were African American
(54.2%), compared with both substance-dependent pa-
tients (30.2%) and PD patients (27.1%) ( , 22x  16.25
df, ). The mean (SD) age of all subjects wasP  .0003
35.4 (9.8) years, with the controls being significantly
younger (32.6 [9.6] years) than either the substance-
dependent patients (36.4 [9.4] years) or the PD patients
(35.7 [10.2] years) ( , ).F[2, 338]  3.83 P  .023
Among the 162 patients with a lifetime DSM-III-R sub-
stance-use disorder (American Psychiatric Association
1987), 132 patients had alcohol dependence, 93 patients
had cocaine dependence, and 55 patients had opiate
dependence (some subjects had more than one sub-
stance-dependence diagnosis). Among the 107 PD pa-
tients, breakdown by diagnosis is as follows (some sub-
jects received more than one PD diagnosis, including
more than one diagnosis within a cluster). For the MCP
subjects, there were 21 dramatic-cluster diagnoses (an-
tisocial, histrionic, narcissistic, or borderline), 20 anx-
ious-cluster diagnoses (obsessive-compulsive, passive-
aggressive, dependent, or avoidant), and 18 odd-cluster
diagnoses (paranoid, schizoid, or schizotypal), and 23
subjects received a diagnosis of PD not otherwise spec-
ified (NOS). For the MSSOM subjects, there were totals
of 39 dramatic-cluster diagnoses, 39 anxious-cluster di-
agnoses, 26 odd-cluster diagnoses, and 4 NOS diagno-
ses. For the UCHC subjects, there were 2 dramatic-clus-
ter diagnoses, 2 anxious-cluster diagnoses, 1 odd-cluster
diagnosis, and 2 NOS diagnoses.
Preparation of DNA and Polymorphisms Studied
DNA was extracted from whole blood by standard
methods. Genotyping was accomplished at the VA Con-
necticut Healthcare System, West Haven Campus. A Per-
kin Elmer Cetus model 9600 PCR cycler was used for
all reactions; all reactions used the hot-start technique.
Exon 3 VNTR.—The conditions used have been de-
scribed elsewhere (Grice et al. 1996).
Exon 3 single-base substitution (glycine 194).—The
primers were ex3-1f and ex3-1r, as reported by Seeman
et al. (1994). The PCR product was digested by use of
AccI (New England Biolabs), to recognize the polymor-
phism (Seeman et al. 1994).
Exon 1 13-bp deletion and 12-bp insertion/dele-
tion.—We amplified a region of exon 1 containing both
polymorphisms, using the 5′ primer (Ex1S) described by
Catalano et al. (1993) and the 3′ primer (519) described
by No¨then et al. (1994) as Chang and Kidd (1997), but
we digested the PCR product with PstI (New England
Biolabs), which cleaves the product into fragments of
∼100 bp and ∼200 bp. The 13-bp deletion occurs in the
shorter fragment, the 12-bp duplication in the longer
fragment.
Statistical Analyses
Hierarchical multiple regression was used to examine
the correlation of novelty-seeking scores with demo-
graphic features, psychiatric diagnostic group, the
DRD4 VNTR genotype, and two-way and three-way
interactions involving the VNTR genotype. In this anal-
ysis, independent variables were entered in five sets, in
the following order: (1) demographics (sex, race, and
age); (2) diagnostic groups (controls, substance-depend-
ent patients, and PD patients); (3) VNTR genotype
(DRD4*7R allele absent vs. one or two alleles present);
(4) all two-way interactions involving the VNTR geno-
type; and (5) the three-way interactions involving the
VNTR genotype (with the exception that the two or-
thogonal diagnostic-group predictors were not allowed
to interact). Demographic variables were centered or ef-
fect coded (1, 1), and two orthogonal dummy variables
were created from the three-level diagnosis. Two or-
thogonal contrasts (controls vs. patients and substance-
dependent patients vs. PD patients) were used to ex-
amine the difference in novelty-seeking scores among the
diagnostic groups.
This analytic approach made it possible to control for
the effects of each of the demographic and diagnosis-
predictor variables prior to examination of the effect of
genotype on novelty-seeking scores. The subsequent hi-
erarchical entry of the two-way and then the three-way
interactions served to clarify further the main effects that
were observed, while insuring that the higher-order in-
teractions were orthogonal to all lower-order antecedent
effects.
A similar analytic approach was used to examine the
correlation of the exon 1 12-bp insertion and the null
mutations, with novelty-seeking scores. Each of these
genotypes was examined in separate regression analyses.
In both cases, however, the unacceptably small cell sizes
(table 1) that would have resulted from the use of in-
teraction terms as predictor variables led to the exam-
ination of only the main effects of (1) demographic var-
iables, (2) diagnostic groups, and (3) genotype on
novelty-seeking scores. Analysis of the exon 1 12-bp
insertion was performed by use of the presence or ab-
sence of this variant alone. The exon 1 13-bp deletion
is a literal null mutation, and the other exon 3 mutation,
D4194Glycine, substantially decreases ligand binding. Be-
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Table 1
Allele Frequencies for DRD4 Polymorphisms
POLYMORPHISM AND
SUBJECT GROUP 2n
ALLELE FREQUENCY
2 Repeats 3 Repeats 4 Repeats 5 Repeats 6 Repeats 7 Repeats 8 Repeats 10 Repeats
Exon 3 VNTR:
European American:
Normal controls 66 .045 .000 .697 .045 .000 .182 .030 .000
PD 156 .096 .032 .615 .000 .006 .250 .000 .000
Substance dependent 210 .090 .052 .671 .010 .014 .152 .010 .000
Total 432 .086 .037 .655 .012 .009 .192 .009 .000
African American:
Normal controls 78 .038 .013 .628 .038 .000 .218 .051 .013
PD 58 .069 .000 .724 .034 .000 .138 .034 .000
Substance dependent 98 .061 .000 .602 .051 .020 .245 .020 .000
Total 234 .056 .004 .641 .043 .009 .209 .034 .004
Duplication Present Duplication Absent
Exon 1 12-bp duplication:
European American:
Normal controls 58 .914 .086
PD 156 .936 .064
Substance dependent 218 .931 .069
Total 432 .931 .069
African American:
Normal controls 72 .944 .056
PD 58 .931 .069
Substance dependent 92 .967 .033
Total 222 .950 .050
Polymorphism Absent Polymorphism Present
Exon 1 13-bp deletion:
European American:
Normal controls 54 1.000 .000
PD 156 .987 .013
Substance dependent 216 .977 .023
Total 426 .984 .016
African American:
Normal controls 72 1.000 .000
PD 58 1.000 .000
Substance dependent 92 1.000 .000
Total 222
1.000 .000
D4194Glycine D4194Valine
Exon 3 D4194Glycine mutation:
European American:
Normal controls 58 .000 1.000
PD 156 .000 1.000
Substance dependent 222 .005 .995
Total 436 .002 .998
African American:
Normal controls: 78 .064 .936
PD 58 .034 .966
Substance dependent 94 .032 .968
Total 230 .043 .957
NOTE.—For some individuals, genotypes for all four systems were not available.
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cause of the similarity of the predicted effect of these
two mutations, in the reduction or the elimination of
protein function, and the relative rarity of the inactive
or the much less active variant forms, we considered
together the groups having either of these mutations.
For comparison of DRD4 allele frequency by group,
2#2 x2 was used. To ascertain possible deviation from
HWE expectations for DRD4*7R observations, we used
the program HWsim (described in Cubells et al. 1997).
Results
Multivariate Linear Regression with the VNTR
Polymorphism
The demographic independent-variable set accounted
for a significant proportion of the variance in novelty-
seeking scores ( , , ).2F[3, 329]  5.96 R  .052 P  .001
Two of the three demographic variables were significant
in the final regression equation. Sex was not a significant
predictor ( , ). However, raceF[1, 319]  0.67 P  .41
was a significant predictor ( ,F[1, 319]  6.67 P 
), with European Americans having higher novelty-.010
seeking scores (mean 20.3, SD 6.7) than African Amer-
icans (mean 18.6, SD 5.7). Age also was a significant
predictor ( , ), with youngerF[1, 319]  15.65 P ! .001
subjects having higher novelty-seeking scores (standard-
ized ).b  .19
The diagnostic independent-variable set also ac-
counted for significant variance ( ,F[2, 327]  44.85
, ). The two patient groups had higher2R  .204 P ! .001
novelty-seeking scores (mean 20.5, SD 6.5) than controls
(mean 16.8, SD 5.1) ( , ). Sim-F[1, 319]  22.26 P ! .001
ilarly, substance-dependent patients had higher novelty-
seeking scores (mean 22.7, SD 6.0) than PD patients
(mean 17.1, SD 5.9) ( , ).F[1, 319]  40.71 P ! .001
Although the variance accounted for by the single-
variable genotype set was significant ( ,F[1, 326]  6.69
, ), it accounted for only ∼1.5% of2R  .015 P  .010
the variance in novelty-seeking scores. Interestingly, sub-
jects without the DRD4*7R allele had higher novelty-
seeking scores (mean 20.4, SD 6.5) than subjects with
one or two copies of that allele (mean 18.5, SD 6.2)
( , ).F[1, 319]  5.36 P  .021
The variance accounted for by the two-way-interac-
tion set was not significant ( , ).F[5, 321]  .66 P  .66
Nonetheless, it was retained in the equation, because the
set of higher-order (i.e., three-way) interactions ac-
counted for significant variance ( ,F[2, 319]  5.96
, ). Of the eight three-way interac-2R  .026 P  .003
tions analyzed, only two were significant. The sex, by
race and by VNTR-genotype interaction, was statisti-
cally significant ( , ). Decom-F[1, 319]  6.37 P  .012
position of the interaction revealed that, among Euro-
pean American females, the absence of the DRD4*7R
allele was associated with significantly higher novelty-
seeking scores (mean 22.8, SD 6.5), compared with the
presence of the DRD4*7R allele (mean 19.6, SD 7.0)
( , ). The presence versus theF[1, 208]  4.66 P  .032
absence of the DRD4*7R allele had no significant im-
pact on novelty-seeking scores for any of the other three
race-by-sex groups. The other three-way interaction that
was statistically significant ( ,F[1, 319]  8.40 P 
) involved the second diagnostic variable (substance-.004
dependent vs. PD patients), by race and by VNTR gen-
otype. Decomposition of the interaction revealed that,
among African American patients with substance depen-
dence, the absence of the DRD4*7R allele was associ-
ated with significantly higher novelty-seeking scores
(mean 23.6, SD 5.1), compared with the presence of the
DRD4*7R allele (mean 19.1, SD 3.6) (F[1, 109] 
, ). The presence versus the absence of the5.89 P  .017
DRD4*7R allele had no significant impact on novelty-
seeking scores for any of the other three race-by-diag-
nostic groups (fig. 1).
Repetition of the entire analysis, by use of genotype
as a continuous independent variable (i.e., 0, 1, or 2
copies of the DRD4*7R allele), produced nearly iden-
tical results. Furthermore, examination of the study site
(UCHC, MCP, or MSSOM) as a main effect as well as
the interaction of the study site and the VNTR genotype
revealed that these were not significant predictors of nov-
elty-seeking scores, so it was removed from the analysis.
Multivariate Linear Regression with the Null Alleles
A total of 18 subjects heterozygous for the null or the
very low activity allele were observed. (For the African
American subjects, all of the heterozygotes are hetero-
zygotes for glycine 194, whereas, for the European
American subjects, all but one are heterozygous for the
13-bp deletion.)
As in the first analysis, the demographic independent-
variable set accounted for a significant proportion of the
variance in novelty-seeking scores ( ,F[3, 316]  6.58
, ). Although sex was not a significant2R  .059 P ! .001
predictor ( , ), both raceF[1, 312]  2.03 P  .16
( , ) and age (F[1, 312]  6.887 P  .009 F[1, 312] 
, ) were significantly correlated with nov-11.44 P  .001
elty-seeking scores. Consistent with the results of the first
analysis, European Americans and younger subjects had
higher novelty-seeking scores.
The diagnostic independent-variable set also ac-
counted for significant variance ( ,F[2, 314]  41.16
, ). The two patient groups had higher2R  .195 P ! .001
novelty-seeking scores than controls (mean 16.8, SD 5.1)
( , ). Similarly, substance-de-F[1, 312]  13.29 P ! .001
pendent patients had higher novelty-seeking scores than
PD patients ( , ).F[1, 312]  63.59 P ! .001
The variance accounted for by the single-variable ge-
notype set was not significant ( ,F[1, 313]  .24 P 
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Figure 1 DRD4 exon 3 genotype and novelty seeking, by TPQ. NC  normal control; PD  personality disordered; and SD substance
dependent.
). Between subjects with one of the null alleles.63
( ; mean 19.1, SD 5.5) and those without a nulln  18
allele ( ; mean 19.9, SD 6.5), there was no dif-n  302
ference in novelty-seeking scores.
Multivariate Linear Regression with the Exon 1 12-bp
Insertion
As in the other analyses, the demographic independ-
ent-variable set accounted for a significant proportion
of the variance in novelty-seeking scores (F[3, 323] 
, , ). Two of the three demo-26.16 R  .054 P ! .001
graphic variables also were significant in the final re-
gression equation. Sex was not a significant predictor
( , ). Both race (F[1, 319]  2.75 P  .098 F[1, 312] 
, ) and age ( , )6.01 P  .015 F[1, 319]  10.63 P  .001
were significant predictors, with European Americans
and younger subjects having higher novelty-seeking
scores.
The diagnostic independent-variable set also ac-
counted for significant variance ( ,F[2, 321]  39.25
, ). Patients had higher novelty-seek-2R  .186 P ! .001
ing scores than controls ( , ),F[1, 319]  12.95 P ! .001
with substance-dependent patients having higher nov-
elty-seeking scores than PD patients (F[1, 319] 
, ).60.28 P ! .001
The variance accounted for by the single-variable ge-
notype set was not significant ( ,F[1, 320]  2.44 P 
). Between subjects with the exon 1 12-bp insertion.12
( ; mean 21.2, SD 6.9) and those without thatn  38
variant ( ; mean 19.6, SD 6.4), there was no dif-n  289
ference in novelty-seeking scores.
HWE and Allele-Frequency Comparisons
If the DRD4*7R allele affects novelty seeking, it also
might influence assortative mating, and this could cause
a deviation from HWE. However, the expected number
of DRD4*7R homozygotes (under HWE) was observed
in each population: for European American subjects, the
observations for DRD4*7R homozygotes and hetero-
zygotes and for other genotypes were 7, 69, and 140,
respectively; for deviation from HWE expectations,
(1 df) (not significant). For African American2x  0.18
subjects, the corresponding figures were 7, 35, and 75;
(1 df) (not significant). There were no signif-2x  1.09
icant allele-frequency differences between the high nov-
elty-seeking (substance dependent) and low novelty-
seeking (normal control  PD) groups, for any of the
four polymorphic systems.
Discussion
We observed no significant increase in DRD4*7R al-
lele frequency in any group, despite considerable vari-
ability in the level of novelty seeking among subgroups;
the only significant associations seen were lower novelty
seeking in European American women and in substance-
dependent African Americans with a DRD4*7R allele.
(Interestingly, Malhotra et al. [1996] reported a signif-
icant association between the DRD4*7R allele and de-
creased novelty seeking in Finnish alcoholic offenders.)
This suggests that the DRD4*7R allele is not associated
with increased novelty seeking in these subject groups,
as reported elsewhere for other subjects (Benjamin et al.
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1996; Ebstein et al. 1996). We used the same measure
of novelty seeking as that used by Ebstein et al. (1996),
so a direct comparison with their results is possible. No
other DRD4 polymorphism was associated with novelty
seeking in any subgroup of either population. Power
analyses based on the reported figures of Benjamin et al.
(1996) suggested that a sample size of 328 (a threshold
that we slightly exceeded) would have been adequate to
detect an effect of the magnitude that they reported for
the VNTR (0.4 SD) (two-tailed test), with anda  .05
90% power (Brent et al. 1993).
We studied groups of subjects for whom genetic de-
terminants of novelty seeking could differ (substance de-
pendent and non–substance dependent, Americans of
European ancestry and of African ancestry, and males
and females), but, overall, our sample size was larger
than that for any previous study. Since the coding-se-
quence polymorphisms studied here are presumed to af-
fect function directly, population stratification should
not be a major issue. Furthermore, the data analytic
approach employed made it possible to control for sub-
group differences in novelty seeking, prior to exami-
nation of the impact of a DRD4 genotype.
We examined all known coding-sequence DRD4
polymorphisms, some of which clearly have a greater
effect on function than the exon 3 VNTR. Heterozygotes
for DRD4 exon 1 or exon 3 null mutations either should
express approximately one-half the usual amount of D4
dopamine-receptor protein (exon 1 null) or should have
one-half nearly nonfunctional D4 receptors (exon 3
null). For D4 receptor–related phenotypes, these indi-
viduals with reduced D4 function should show some
variation, compared with individuals with two alleles
encoding a functional receptor. However, we found that
there was no difference in novelty seeking, for the small
observed number of null heterozygotes. This should pro-
vide a good test of the hypothesis of an association of
DRD4 alleles with novelty seeking, unless the DRD4*7R
allele represents a large gain of function, that is, unless
the difference between the DRD4*7R allele and the
DRD4*4R allele (for example) is quantitatively greater
than the difference between the DRD4*4R allele and
zero function. Our results with the exon 1 12-bp du-
plication argue against the hypothesis that it is this var-
iant that conveys the primary phenotypic effect.
There are several possible explanations for this failure
to observe higher novelty seeking in subjects with the
DRD4*7R allele, as observed by Ebstein et al. (1996)
and by Benjamin et al. (1996). A true association could
be present only in certain populations or in certain
ranges of the phenotype. The DRD4*7R allele thus
could have a small effect on increasing novelty seeking
only in the normal range, in the context of other genetic
and environmental factors that are more important.
However, our results do not support such an association,
even in the normal range. Another possibility is that the
association could be present—but for a phenotype that
is not ideally measured by personality measures such as
the TPQ and that is interacting with those measures.
Consistent with this hypothesis, our previous data (Grice
et al. 1996) do support a physiological role for DRD4
variation. In general, this hypothesis is also consistent
with the fact that we did observe a significant relation-
ship between novelty seeking and the DRD4*7R allele,
in our African American substance-dependent subjects
and European American female subjects, but in the di-
rection opposite that observed by Ebstein et al. (1996)
and by Benjamin et al. (1996). This could be explained
by an unidentified interaction between DRD4 alleles and
personality.
Alternatively, since the exon 3 VNTR affects protein
sequence on a gross level, it may have been assumed
incorrectly that this variation contributes directly to the
protein differences observed: it also could be in linkage
disequilibrium with a still unknown polymorphism that
has a greater effect on function. In different populations
(e.g., African American and European American), the
DRD4*7R VNTR allele could be in linkage disequilib-
rium with different alleles of this putative polymorphism
actually conveying a phenotypic effect. This could ac-
count for our observation and the Malhotra et al. (1996)
observation of the DRD4*7R allele being associated
with low novelty seeking in African American and Finn-
ish subjects with substance-use disorders and for the Eb-
stein et al. (1996) and Benjamin et al. (1996) observa-
tions of the same allele being associated with high
novelty seeking in European American or in White Mid-
dle Eastern subjects. This still could not explain why we
saw no association in our normal control and PD sub-
jects, and the lack of an effect of the DRD4 mutations
either eliminating or greatly reducing D4 dopamine-re-
ceptor function would remain problematic.
This failure to replicate an association between the
DRD4*7R allele and higher novelty seeking may simply
be a chance event, but the possibility that the present
results represent a false negative should be viewed in the
context of the absence of previous data showing an as-
sociation between the DRD4*7R allele and diagnoses
associated with high novelty seeking, such as alcoholism.
We note that our finding, to a limited extent, is consistent
with the earlier observations that DRD4 alleles are as-
sociated with novelty seeking. We conclude that, if ge-
netic variation at the DRD4 locus exerts an effect on
human novelty seeking, it is likely to be through a mu-
tation in linkage disequilibrium with the exon 3 VNTR
rather than as a direct consequence of that variation.
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